Suppr超能文献

心脏辅助装置在矫正型大动脉转位患者中的植入:一例报告及其临床挑战

HeartWare Ventricular Assist Device Placement in a Patient With Corrected Dextro-Transposition of Great Arteries: A Case Report and Its Clinical Challenges.

作者信息

Sehgal Sankalp, Ramachandran Sujatha, Leff Jonathan D

机构信息

Hahnemann University Hospital/Drexel University College of Medicine, Philadelphia, PA, USA

Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.

出版信息

Semin Cardiothorac Vasc Anesth. 2015 Sep;19(3):243-7. doi: 10.1177/1089253214566886. Epub 2015 Jan 18.

Abstract

Given the improved survival in patients with corrected dextro-transposition of great arteries (D-TGA), it has evolved into an adult congenital heart defect. It is important to understand the management and complications observed in this population that eventually progresses to systemic ventricular failure requiring cardiac transplantation. Our case focuses on the rapid right ventricle (RV) deterioration of a patient with corrected D-TGA following a surgical procedure requiring systemic support. With such patients awaiting heart transplantation, there are limited assist devices available for RV support and no right ventricular assist device is approved for destination therapy yet. Current indications for implantation of the HeartWare ventricular assist device (HVAD) are limited by the Food and Drug Administration (FDA) to the left ventricle support as a bridge to transplantation. However, its use in the United States for right-sided support has rarely been described for adult congenital defects. In this case, a HeartWare assist device was used to provide systemic support as a bridge to cardiac transplant. The size and implantation design of the HVAD makes it a promising option for patients with this challenging patient population and RV failure as a late complication.

摘要

鉴于大动脉转位(D-TGA)矫正术后患者生存率的提高,该病已发展成为一种成人先天性心脏缺陷。了解这一最终进展为需要心脏移植的系统性心室衰竭人群中所观察到的管理方法和并发症很重要。我们的病例聚焦于一名接受需要全身支持的手术后,矫正型D-TGA患者右心室(RV)的迅速恶化。对于此类等待心脏移植的患者,可用于右心室支持的辅助装置有限,且尚无右心室辅助装置被批准用于终末期治疗。目前,心脏辅助装置(HVAD)植入的指征受到美国食品药品监督管理局(FDA)的限制,仅限于作为移植桥梁的左心室支持。然而,在美国,其用于右侧支持治疗成人先天性缺陷的情况鲜有报道。在此病例中,使用了心脏辅助装置(HVAD)来提供全身支持,作为心脏移植的桥梁。HVAD的尺寸和植入设计使其成为这一具有挑战性的患者群体和作为晚期并发症的右心室衰竭患者的一个有前景的选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验